GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Cyclically Adjusted Book per Share

BioLine Rx (BioLine Rx) Cyclically Adjusted Book per Share : $8.01 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioLine Rx's adjusted book value per share for the three months ended in Dec. 2023 was $0.183. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.01 for the trailing ten years ended in Dec. 2023.

During the past 12 months, BioLine Rx's average Cyclically Adjusted Book Growth Rate was -11.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioLine Rx was -15.80% per year. The lowest was -17.10% per year. And the median was -16.45% per year.

As of today (2024-04-28), BioLine Rx's current stock price is $0.6116. BioLine Rx's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $8.01. BioLine Rx's Cyclically Adjusted PB Ratio of today is 0.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioLine Rx was 0.20. The lowest was 0.09. And the median was 0.15.


BioLine Rx Cyclically Adjusted Book per Share Historical Data

The historical data trend for BioLine Rx's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cyclically Adjusted Book per Share Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.46 15.69 12.33 9.31 8.01

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.31 9.39 8.34 7.54 8.01

Competitive Comparison of BioLine Rx's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted PB Ratio falls into.



BioLine Rx Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLine Rx's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.183/129.4194*129.4194
=0.183

Current CPI (Dec. 2023) = 129.4194.

BioLine Rx Quarterly Data

Book Value per Share CPI Adj_Book
201403 14.269 99.695 18.523
201406 12.876 100.560 16.571
201409 11.812 100.428 15.222
201412 12.197 99.070 15.934
201503 15.196 99.621 19.741
201506 14.531 100.684 18.678
201509 13.908 100.392 17.929
201512 13.028 99.792 16.896
201603 12.229 100.470 15.753
201606 11.315 101.688 14.401
201609 10.262 101.861 13.038
201612 9.212 101.863 11.704
201703 8.671 102.862 10.910
201706 9.009 103.349 11.282
201709 8.504 104.136 10.569
201712 7.550 104.011 9.394
201803 6.912 105.290 8.496
201806 6.413 106.317 7.807
201809 5.632 106.507 6.844
201812 5.393 105.998 6.585
201903 4.761 107.251 5.745
201906 4.258 108.070 5.099
201909 3.876 108.329 4.631
201912 2.923 108.420 3.489
202003 2.393 108.902 2.844
202006 1.479 108.767 1.760
202009 1.255 109.815 1.479
202012 0.946 109.897 1.114
202103 1.517 111.754 1.757
202106 1.591 114.631 1.796
202109 1.500 115.734 1.677
202112 1.428 117.630 1.571
202203 1.330 121.301 1.419
202206 1.181 125.017 1.223
202209 0.902 125.227 0.932
202212 0.826 125.222 0.854
202303 0.636 127.348 0.646
202306 0.342 128.729 0.344
202309 0.203 129.860 0.202
202312 0.183 129.419 0.183

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


BioLine Rx  (NAS:BLRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioLine Rx's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.6116/8.01
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioLine Rx was 0.20. The lowest was 0.09. And the median was 0.15.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioLine Rx Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.